Research on Chemical Intermediates

, Volume 42, Issue 6, pp 5709–5721 | Cite as

A facile and economic method for the synthesis of (S)-N-Boc-3′-hydroxyadamantylglycine

  • Jie Li
  • Xue Jiang
  • Run Gan
  • Ming Zhang
  • Xinmei Pan
  • Xiangnan Hu


(S)-N-Boc-3′-hydroxyadamantylglycine (I) is an important intermediate of saxagliptin for type 2 diabetes mellitus (T2DM). It was prepared from 1-adamantanecarboxylic acid(1) via mild reaction with sulfuric acid/nitric acid, VHA reagent (SOCl2/DMF) and sodium diethyl malonate, then was treated with hydrolysis, decarboxylation, alkalization and oxidation to give 2-(3-hydroxy-1-adamantyl)-2-oxoacetic acid (4), then through oximation, reduction and (Boc)2O protection to give the N-Boc-3′-hydroxyadamantylglycine(6), then was treated with quinidine to get (S)- N-Boc-3′-hydroxyadamantylglycine(I) and quinine to get (R)–N-Boc-3′-hydroxyadamantylglycine(II). Finally, Compound II was racemized by dicyclohexylcarbodiimide (DCC) and sodium hydride (NaH) to afford compound 6. In this route, the overall yield of preparing compound I was about 35 % and the enantiomeric excess (ee) reach to 99 %. This route provided a novel idea for the preparation of (S)-N-Boc-3′-hydroxyadamantylglycine.


Saxagliptin VHA reagent Intermediate Racemization Chiral separation 



We deeply appreciate the financial support of this research by a grant from the graduate scientific research and innovation projects of Chongqing Education Committee (No. CYS15142). We are also grateful for all that Chongqing Medical University and Chongqing Research Center for Pharmaceutical Engineering have done for accomplishing this study.

Compliance with ethical standards

Conflicts of interest

The authors declare no conflict of interest.


  1. 1.
    International Diabetes Federation-Key Findings, IDF Diabetes Atlas Seventh Edition Poster Update 2015.
  2. 2.
    M.L. Mohler, Y. He, Z. Wu et al., Recent and emerging anti-diabetes targets [J]. Med. Res. Rev. 29(1), 125–195 (2009)CrossRefGoogle Scholar
  3. 3.
    B.M. Squibb, ONGLYZA (saxagliptin) Tablets Prescribing Information (Bristol-Myers Squibb, Princeton, 2011)Google Scholar
  4. 4.
    V.A. Soloshonok, C. Cai, V.J. Hruby, Stereochemically defined C-substituted glutamic acids and their derivatives. 1. An efficient asymmetric synthesis of (2S,3S)-3-methyl- and -3-trifluoromethylpyroglutamic acids[J]. Tetrahedron 55, 12031–12044 (1999)CrossRefGoogle Scholar
  5. 5.
    J.L. Aceña, A.E. Sorochinsky, V.A. Soloshonok, Recent advances in asymmetric synthesis of a-(trifluoromethyl)-containing amino acids. Synthesis 44, 1591–1602 (2012)CrossRefGoogle Scholar
  6. 6.
    P. Etayo, A. Vidal-Ferra´n, Rhodium-catalyzed asymmetric hydrogenation as a valuable synthetic tool for the preparation of chiral drugs. Chem. Soc. Rev. 42, 728–754 (2013)CrossRefGoogle Scholar
  7. 7.
    J. Wang, X. Liu, X. Feng, Asymmetric strecker reactions. Chem. Rev. 111, 6947–6983 (2011)CrossRefGoogle Scholar
  8. 8.
    K. Undheim et al., The Scho¨llkopf chiron and transition metal mediated reactions, a powerful combination for stereoselective construction of cyclic a-quaternary-a-amino acid derivatives. Amino Acids 34, 357–402 (2008)CrossRefGoogle Scholar
  9. 9.
    A.E. Sorochinsky et al., Asymmetric synthesis of a-amino acids via homologation of Ni(II) complexes of glycine Schiff bases. Part: 1 alkyl halide alkylations. Amino Acids 45, 691–718 (2013)CrossRefGoogle Scholar
  10. 10.
    A.E. Sorochinsky et al., Asymmetric synthesis of a-amino acids via homologation of Ni(II) complexes of glycine Schiff bases. Part 2: Aldol, Mannich addition reactions, deracemization and (S) to (R) interconversion of a-amino acids. Amino Acids 45, 1017–1033 (2013)CrossRefGoogle Scholar
  11. 11.
    J.L. Aceña et al., Asymmetric synthesis of a-amino acids via homologation of Ni(II) complexes of glycine Schiff bases Part 3 Michael addition reactions and miscellaneous transformations. Amino Acids 46, 2047–2073 (2014)CrossRefGoogle Scholar
  12. 12.
    Y. Nian et al., Recyclable ligands for the non-enzymatic dynamic kinetic resolution of challenging a-amino acids. Angew. Chem. Int. Ed. 54, 12918–12922 (2015)CrossRefGoogle Scholar
  13. 13.
    T.C. Vu, D.B. Brzozowski, R. Fox, Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof [P]. WO 2004/052850 A2 (2004)Google Scholar
  14. 14.
    R.L. Hanson, S.L. Goldberg, D.B. Brzozowski, Preparation of an amino acid intermediate for the dipeptidyl peptidase IV inhibitor, saxagliptin, using a modified phenylalanine dehydrogenase [J]. Adv. Synth. Catal. 349, 1369–1378 (2007)CrossRefGoogle Scholar
  15. 15.
    D.J. Augeri, J.A. Robl, D.A. Betebenner et al., Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes [J]. J. Med. Chem. 48, 5025–5037 (2005)CrossRefGoogle Scholar
  16. 16.
    D Benito-Garragori, W Felzmann, K Knepper et al., Process for the reductive amination of α-keto carboxylic acids. WO 2012/028721 A1 (2012)Google Scholar
  17. 17.
    Y. Chen, A. Wang, Z. Tao et al., A facile synthesis of saxagliptin intermediate N-Boc-3′-hydroxyadamantylglycine [J]. Res. Chem. Intermed. 41, 4113–4121 (2015)CrossRefGoogle Scholar
  18. 18.
    A. Wang, Y. Deng et al., A convenient method for the synthesis of (S)-N-boc-3-hydroxyadamantylglycine: a key intermediate of saxagliptin [J]. Lett. Org. Chem. 11, 627–663 (2014)CrossRefGoogle Scholar
  19. 19.
    T.C. Vu, D.B. Brzozowski, R. Fox et al. Methods and compounds producing dipeptidyl peptidase IV inhibiors and intermediates thereof. WO 2004/052850 A2 (2004)Google Scholar
  20. 20.
    V Reddy, R Mitra, A Kumar, P. Ramakrishna, A process for industrial preparation for [(S)-N-tert butoxycarbonyl-3-hydroxy]adamantylglycine. WO 2014/057495 A1 (2014)Google Scholar
  21. 21.
    J. Dong, Y. Gong, J. Liu, X. Chen, X. Wen, H. Sun, Synthesis and biological evaluation of all eight stereoisomers of DPP-IV inhibitor saxagliptin. Bioorg. Med. Chem. 22, 1383–1393 (2014)CrossRefGoogle Scholar
  22. 22.
    M. Politino, M.M. Cadin, P.M. Skonezny, J.G. Chen, Process for preparing dipeptidyl IV inhibitors and intermediates therefor [P]. WO 2005106011 (2005)Google Scholar
  23. 23.
    S.A. Savage, G.S. Jones, S. Kolotuchin, S.A. Ramrattan, T. Vu, R.E. Waltermire, Preparation of saxagliptin, a novel DPP-IV inhibitor. Org. Process Res. Dev. 13(6), 1169–1176 (2009)CrossRefGoogle Scholar
  24. 24.
    J.K. Li, H.R. Zhou, J. Peng et al., Synthesis of 2-(3-hydroxy-1-adamantyl)-2-glyoxylic Acid. Chin. J. Pharm. 43(4), 251–253 (2012)Google Scholar
  25. 25.
    Y. Feng, Y.J. Chen, J. Peng et al., Optimization of the synthesis process of 2- (3- hydroxy- 1- adamantyl)- 2-oxoacetic acid by the central composite design- response surface methodology. Chem. Res. Appl. 2, 194–199 (2013)Google Scholar
  26. 26.
    S.L. Ferreira, R.E. Bruns, J.M. David et al., Statistical designs and response surface techniques for the optimization of chromatographic systems. J. Chromatogr. A 1158(1–2), 2–14 (2007)CrossRefGoogle Scholar
  27. 27.
    W Thorsten, Racemisation of (R)-N-BOC-3-hydroxyadamantyl glycine [P]. WO 2011/117393 A1 (2011)Google Scholar
  28. 28.
    V.V. Pozdnyakov, I.K. Moiseev, Synthesis of 3-R-1-acetyladamantanes by substitution in 3-chloro- and 3-hydroxy-1-acetyladamantanes. Russ. J. Org. Chem. 39(5), 739–741 (2003)CrossRefGoogle Scholar
  29. 29.
    J.D. Godfrey Jr., R.T. Fox et al., Novel 1,4-homofragmentation via an α-lactone [J]. J. Org. Chem. 71, 8647–8650 (2006)CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2016

Authors and Affiliations

  • Jie Li
    • 1
  • Xue Jiang
    • 1
  • Run Gan
    • 1
  • Ming Zhang
    • 1
  • Xinmei Pan
    • 1
  • Xiangnan Hu
    • 1
  1. 1.Pharmacy CollegeChongqing Medical UniversityChongqingPeople’s Republic of China

Personalised recommendations